Invescap CEO, Marc-André Pépin announces Grand Court of the Cayman Islands’ petition withdrawal order

Claims of fraud made by former fund personnel, SPI Investment Fund, deemed to be unfounded.

GENEVA, Aug. 9, 2022 /PRNewswire/ — Swiss investment firm, Invescap SA, has announced the unequivocal dismissal of a petition alleged against it and CEO Marc-André Pépin, by former fund personnel.

After rigorous scrutiny from both the Cayman Islands Monetary Authority (CIMA) and the Grand Court of the Cayman Islands, the petition logged against the company was deemed to be unfounded.

The petition, reviewed and ordered by the Hon. Justice David Doyle, was therefore withdrawn on 8 July 2022.

Commenting on the withdrawal of the petition, asset management specialist and CEO of Invescap, Mr. Pépin said: “The termination of a directorship contract is always unfortunate, but the long-term security of our client’s investments has always been our top priority.”

“We are happy that these past four months of thorough review are completed concluding to no wrongdoing and that the claim of fraudulent activity has been quashed”.  Pepin continued: “We consider this situation to be closed and look forward to moving ahead.”

For more information about Invescap, visit: https://www.invescap.ch/

About Invescap

Invescap SA is a Switzerland-based investment firm founded by Dr. Marc-Andrè Pépin. Invescap works internationally focusing on high-yield options, portfolio diversification and risk analysis.

Contact

e-mail: info@invescap.ch

‫‫تؤكد TCL ريادتها في أجهزة تلفزيون Mini LED في عام 2022

هونك كونغ، 9 غشت/آب 2022 / PRNewswire / — شهدت العقود الأربعة الماضية، مدفوعة بثقافة الإبداع والابتكار، نموًا سريعًا لشركة TCL لتصبح واحدة من الشركات المهيمنة في صناعة التلفزيون العالمية مع إمكانات التكامل الرأسي ومجموعة منتجات متنوعة بما في ذلك أجهزة التلفزيون والأجهزة الصوتية الحائزة على جوائز.

مستقبل شاشة LCD : تقنية Mini LED

توفر تقنية Mini LED تباينًا وسطوعًا عاليين ومظهرًا رفيعًا للغاية والعديد من مناطق التعتيم المحلية، وتوفر لسلسلة 2022 TCL TV صورة وجودة ألوان استثنائية. التعامل بسهولة مع الصور سريعة الحركة – تعد تلفزيونات Mini LED مثالية للحركة الرياضية والأفلام الشهيرة – وتوفر انسيابية بصرية مثالية، دون أي وميض أو اهتزاز.

تفخر TCL بإنجازاتها في تقنية Mini LED منذ عام 2018، وقد تلقت الشركة مجموعة من الموافقات من وسائل الإعلام والجمعيات المهنية. في عام 2022، أطلقت TCL أحدث جيل لها من تقنية Mini LED ، مع المزيد من المزايا الرئيسية الجديدة للمستخدمين:

  • تحكم فائق الدقة في الإضاءة بمعدل 16 بت لتقديم ألوان أكثر ثراءً وتفاصيل أكثر
  • Round Halo Mini LED للقضاء على هالة مزهرة من الأجسام البيضاء على خلفيات سوداء نقية
  • الدخول المباشر لمصباح TCL Mini LED لضمان أن تكون الأجسام سريعة الحركة أكثر وضوحًا ودقة على الشاشة
  • جودة موحدة Mini LED للحصول على صورة موحدة اللون
  • ديمورا إضاءة خلفية TCL Mini LED مع تحكم موحد في الإضاءة (لا يوجد ضوء كشاف، لا رقعة رمادية، لا يوجد تأثير شاشة متسخ)

من خلال الاستفادة من ميزة المحرك الأول في مساحة Mini LED ، حققت TCL نموًا كبيرًا في حجم المبيعات لشاشاتها الذكية المتوسطة إلى المتطورة في عام 2021. زادت أحجام مبيعات الشاشات الذكية TCL QLED و Mini LED بنسبة 53.8٪ و 50.5٪ على أساس سنوي، على التوالي.

واجهة تقنية Mini LED : OD Zero Mini LED

يتميز OD Zero Mini LED بأصغر شريحة LED ويضاعف عدد مناطق التعتيم المحلية. من خلال تصغير شريحة LED إلى الحد الأدنى، فإنها تمكن TCL من زيادة دقة الإضاءة الخلفية إلى أقصى حد لتقديم التباين والسطوع المطلقين. من خلال إزالة المسافة الضوئية القياسية، تستطيع TCL أيضًا بناء أنحف أجهزة تلفزيون ذات إضاءة مباشرة على الإطلاق، في عام 2022، تم اختيار تلفزيون TCL’s 8K OD Zero Mini LED – X9 (X925 PRO) – لتكريمه بجائزة CES® 2022 للابتكار، حيث حصل بجائزة “أفضل ابتكار” المرموقة.

2022 TCL TV Series : مجموعة واسعة جدًا من أجهزة التلفزيون من النماذج الأساسية إلى الطرز الرئيسية، لجميع الاستخدامات والاحتياجات والتوقعات.

  • تجمع تلفزيونات TCL X Series Mini LED بين TCL’s Mini LED وتقنية QLED و 8K . توفر سلسلة X للمشاهدين تجربة مشاهدة لا مثيل لها بفضل مصابيح LED الأكثر فأكثر التي تنتج المزيد من مناطق التحكم في التباين. ثم يكشف عن مزيد من التفاصيل، والإضاءة اللامعة، ونطاق ديناميكي عالٍ أوسع.
  • تعد تلفزيونات TCL C Series إضافة مهمة لالتزام TCL المستمر بجلب تجربة مشاهدة وترفيه استثنائية 4K Mini LED و QLED للمستخدمين. في عام 2022، تتميز طرز المجموعة المتطورة من سلسلة TCL C (TCL C935 & TCL C835) أيضًا بتقنية Mini LED . تتيح أجهزة التلفزيون هذه، المُحسَّنة بنظام صوتي رائد في الصناعة، يتميز بتقنية Dolby Atmos ، للمستخدمين الاستمتاع باتصال أعمق بجميع أنواع المحتوى المعروضة على الشاشة.

لِـ TCL دور نشط للغاية في مجال الألعاب، حيث يوفر للاعبين شاشات عالية الجودة وخيارات لعب لا حصر لها لتعزيز تجربة الألعاب الخاصة بهم. ميزة 4K Mini LED Line C935 و C835 و 4K QLED Line C735 :

  • معدل تحديث يبلغ 144 هرتز: يوفر استجابة أسرع وصورًا أكثر وضوحًا ولعبًا أكثر سلاسة. مع VRR بمعدل تحديث 144 هرتز، يمكنهم دعم ألعاب ذات معدل إطارات أكبر وأعلى دون تمزيق الشاشة: يمكن أن تتكيف معدلات التحديث الديناميكي مع المحتوى لإنتاج طريقة لعب أكثر سلاسة وانسيابية كما أراد منشئو ألعاب الفيديو.
  • Game Master : سيستمتع اللاعبون الجادون بـ Game Master الذي يوفر ميزات ألعاب إضافية بشكل تلقائي، مع الحركة الأكثر سلاسة وأقل زمن انتقال وأفضل إعدادات للصورة للألعاب مع HDMI 2.1 و ALLM و 144 هرتز VRR و Game Bar .

* قد يختلف مظهر المنتج ووظائفه وتوافره باختلاف البلدان / المناطق.

عن تي سي أل إلكترونيكس

تي سي أل إليكترونيكس كود السهم ( 1070.HK ) هي شركة إلكترونيات استهلاكية سريعة النمو ولاعبة رائدة في صناعة التلفزيون العالمية. تأسست الشركة في العام 1981 وهي تعمل اليوم في أكثر من 160 سوقًا على مستوى العالم. تتخصص تي سي أل في البحث والتطوير وتصنيع منتجات الالكترونيات الاستهلاكية التي تتراوح بين أجهزة التلفزيون والمنتجات السمعية والمنتجات المنزلية الذكية.

رابط الصورة- https://mma.prnewswire.com/media/1873093/144vrr_7_6.jpg

‫  تعد SBS الموزع الرئيسي للحلول القائمة علي blockchain لشركة Modex في منطقة الشرق الأوسط و شمال أفرقيا و أفرقيا 

دبي، الإمارات العربية المتحدة, 9 أغسطس / آب 2022 /PRNewswire/ — شركة Superior Business Solutions Inc المزود للحلول المبتكرة لتكنولوجيا المعلومات من فلوريدا، الولايات المتحدة الأمريكية، مع عمليات في الإمارات العربية المتحدة والكويت وقطر ومصر، أصبحت الموزع الرئيسي للمنتجات والخدمات القائمة على blockchain من Modex في منطقة الشرق الأوسط وشمال أفريقيا وأفريقيا.

SBS becomes the main distributor of Modex's blockchain-based solutions in the MENA Region and Africa


شراكة
SBS الجديدة مع Modex ، المزود لحلول blockchain الرائد، تمكن كلا الطرفين من تقديم خدمات متطورة من شأنها أن تغير طريقة تخزين البيانات والأصول الرقمية ومشاركتها وإدارتها، مما يوفر المزيد من الشفافية وسلامة البيانات.

من خلال شراكتها مع Modex ، تعتزم SBS تقديم الحلول والمنتجات الأكثر ابتكارًا مع الوظائف ذات الصلة التي تدعم سلسلة الكتل في العديد من الصناعات، بما في ذلك الرعاية الصحية والشركات والتمويل. سيسمح هذا للشركتين بدمج حلول blockchain بسلاسة مع أنظمة البيانات الحالية للعملاء لتحقيق كفاءة تشغيلية وأمان وشفافية أعلى.

وأشار الرئيس التنفيذي لـ SBS عادل يوسف إلى أنه “من المتوقع أن ينمو سوق الـ blockchain في الشرق الأوسط وأفريقيا من 199 مليون دولار أمريكي في عام 2021 إلى 7.6 مليار دولار أمريكي بحلول عام 2028؛ ومن المقدر أن يسجل معدل نمو سنوي مركب قدره 68.3% من 2021 إلى 2028 “. “تحتاج الحكومة إلى نمو سريع جدًا في قطاعات مثل الرعاية الصحية، والخدمات المصرفية، والاتصالات، والخدمات اللوجستية، والعديد من القطاعات الأخرى، ويمكن أن يساعد استخدام الحلول القائمة على ال blockchain في تسريع التنمية عبر هذه القطاعات .”SBS Logo

وقال ميهاي إيفاسكو، الرئيس التنفيذي والمؤسس المشارك لشركة Modex : “نظرًا لخبرتهم ومعرفتهم بالشركات المحلية والإقليمية، كان تعيين Superior Business Solutions كموزعنا الرئيسي في منطقة الشرق الأوسط وشمال إفريقيا قرارًا منطقيًا. وبفضل هذه الاتفاقية، ستصل Modex إلى المزيد من العملاء في هذه الأجزاء من العالم، مما يوفر حلولًا قائمة على ال blockchain مصممة بشكل مثالي لتلبية احتياجات أعمالهم”.

فرصة سوق ال Blockchain-as-a-Service

وفقًا لـ Fortune Business Insights ، بلغ حجم سوق Blockchain – as – a – Service (BaaS) العالمي 1.9 مليار دولار أمريكي في عام 2019 ومن المتوقع أن يصل إلى 24.9 مليار دولار أمريكي بحلول عام 2027، ويتوسع بمعدل نمو سنوي مركب قدره 39.5%. يقول التقرير .”من المتوقع أن يؤدي الاعتماد المتزايد لأدوات وخدمات blockchain as a – service (BaaS) بين الشركات الصغيرة والمتوسطة لبناء تطبيق blockchain الخاص بها والعقود الذكية وأنظمة الدفع إلى دفع نمو السوق خلال فترة التنبؤ”. في هذا السياق، تبحث الشركات من جميع الأحجام عن طرق للوصول إلى مزايا خدمات BaaS ، مثل اللامركزية الذكية، وثبات البيانات وسلامتها، والكفاءة العالية، وفعالية التكلفة، والأمن القوي.

قاعدة بيانات Ledger DB لشركة Modex: BaaS على مستوى المؤسسة

مع قاعدة بيانات Ledger DB لشركة Modex ، وهي منصة من فئة الشركات مبنية على الجزء العلوي من حل Blockchain Database® (BCDB) ، تقوم Modex ببناء تطبيقات برمجية ذات صلة لخدمة صناعات محددة وحالات استخدام، والتي يمكن تكييفها وتخصيصها لكل شركة بناءً على نموذج مرن قائم على الاشتراك.

تجلب Modex Ledger DB مجموعة من الميزات التي تسهل الاعتماد السريع لتقنية blockchain عبر كل عمود ويجعل عملية النشر سلسة قدر الإمكان. يسمح للشركات بالتفاعل مع هذه التكنولوجيا بطريقة مبسطة مع تقديم الدعم اللازم لضمان الكفاءة والوظائف العملية. وعلاوة على ذلك، فقد صُممت هذه الشبكة مع وضع الوظائف المؤسسية في الاعتبار لتلبية أشد المتطلبات صرامة فيما يتعلق بالشبكات القابلة للتطوير والجاهزة للإنتاج التي تتكامل مع نظم البيانات المؤسسية القديمة.

يوفر Modex Ledger DB خدمات تدعم سلسلة الكتل من طرف إلى طرف والتي يمكن توسيع نطاقها بسرعة دون انقطاع، مما يوفر أمانًا واستقرارًا عاليين. الحل سهل النشر والاستخدام ويوفر ميزات إدارية معززة لمساعدة الشركات على بناء شبكات ال blockchain الجاهزة للشركات.

نبذة عن Modex

يعمل فريق Modex عالي المهارة المكون من حوالي 100 عضو عبر أربعة مكاتب – لندن وبوخارست ووادي السيليكون وجبل طارق – على إعداد ونشر تطبيقات البرامج ذات الصلة بالإضافة إلى حل ال blockchain كخدمة الذي يمكن أن يدعم مجموعة واسعة من حالات الاستخدام ويسهل التكامل السلس لتكنولوجيا ال blockchain في المنتجات والخدمات على مستوى المؤسسة.

نبذة عن SBS

فريق المهنيين في SBS قابل للتطوير وفقًا لمتطلبات توفير التصميم والبناء ودمج الحلول الذكية المتعددة والمتنوعة سواء بالنسبة للأعمال أو الرعاية الصحية التي تخدم قطاعات مختلفة (إدارية وسريرية ومالية) لمستويات الحكومة الكبيرة والاتحادية في منطقة الشرق الأوسط وشمال إفريقيا وأفريقيا لتمكين الشركات من إدارة وظائفها اليومية بسلاسة وفعالية.

للتواصل الإعلامي: عادل يوسف, adel@sbs-me.com, +971-04 427 7705 http://www.sbs-me.com/

الصورة –  https://mma.prnewswire.com/media/1873983/SBS_and_Modex_blockchain.jpg
الشعار – 
https://mma.prnewswire.com/media/1873984/SBS_Logo.jpg

 

 

 

 

     

Infortrend EonStor GS All Flash U.2 Storage with 100Gb Ethernet Connectivity Tackles Extreme Workloads

TAIPEI, Aug. 9, 2022 /PRNewswire/ — Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage provider, released their flagship EonStor GS all-flash unified storage systems. Featuring the latest Intel Xeon D CPU, PCIe Gen4, and 100GbE, the solutions are perfect for applications requiring low latency and high performance such as database, virtualization, HPC, multimedia and entertainment (M&E).

EonStor GS series is designed for enterprises to flexibly deploy and utilize in a variety of applications. It has been chosen and deployed by several global enterprises and organizations. These organizations include world-renowned car-makers, Czechoslovakia’s Municipal Library, Turkish media conglomerate Ciner Media Group, etc.

Leveraging a series of technological advancements, the EonStor GS U.2 flagship all-flash models (GS 3024UT and GS 4024U) deliver new high performance of the series—up to 1100K IOPS, 24GB/s read and 12GB/s write in end-to-end throughput. The write performance is particularly increased 40% in comparison with the previous U.2 all-flash models. Besides, using 100GbE network connection, compared to 25GbE or 40GbE, allows organizations to enjoy high performance while reduces deployment complexity and total power consumption. Furthermore, the 100GbE supports RDMA and provides up to 12GB/s throughput per port, making it today’s top choice for large-file applications such as HPC and 8K post-production.

In addition to these advancements, the flagship models have retained the series’ favorable features such as scale-out and hybrid-storage capabilities. They also support auto-tiering, which allows the system to automatically prioritize hot data for prompt access, and cold data to be archived.

“Featuring PCIe Gen 4, 100Gb Ethernet connectivity, and flexible scale-out expandability, EonStor GS U.2 series offers significant benefits and performance improvement experiences to HPC and M&E applications,” said Frank Lee, Senior Director of Product Planning at Infortrend.

Learn more about EonStor GS , and EonStor GS 3024UT and EonStor GS 4024U

Contact Infortrend to Make an Inquiry

About Infortrend

Infortrend (TWSE: 2495) has been developing and manufacturing storage solutions since 1993. With a strong emphasis on in-house design, testing, and manufacturing, Infortrend storage delivers performance and scalability with the latest standards, user friendly data services, personal after-sales support, and unrivaled value. For more information, please visit www.infortrend.com

Infortrend® and EonStor® are trademarks or registered trademarks of Infortrend Technology, Inc.; other trademarks are the property of their respective owners.

Ville Parpala Named Regional Sales Manager, Scandinavia for Nikkiso Clean Energy and Industrial Gases Group Europe

TEMECULA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Ville Parpala has been named Regional Sales Manager for Scandinavia.

Ville brings a strong European sales and business development background with an emphasis in international Marine and Industrial market segments. His background in Automation Technology and International Business has proved invaluable to his ability to find new solutions, including utilizing hybrid technologies. He has over 20 years’ experience in Europe, the Middle East and Asia, and has most recently served as Director of Marine Product Marketing for The Switch, as well as Sales management positions with Grundfos, ABB, Marioff and Emerson.

Based in Finland, he will manage and develop business opportunities there and in the Scandinavian territory, including Sweden, Denmark and Norway and will report to Ole Jensen, Vice President, NCEIG Europe.

“We look forward to be able to grow and expand our support of this important market with Ville’s industry and market knowledge, and to further develop opportunities in this region,” according to Ole Jensen.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Stefan Kuijs Named Product Manager for LNG & Hydrogen – The Netherlands – for Nikkiso Clean Energy and Industrial Gases Group Europe

TEMECULA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Stefan Kuijs has been named Product Manager for LNG & Hydrogen for Nikkiso Integrated Cryogenic Solutions serving the Netherlands.

A mechanical engineer, Stefan has specialized education and training in process engineering, and has over ten years’ experience with design, installation, commissioning and start-up of LNG/CNG stations and bio-gas installations. His responsibilities have also included Hydrogen projects with focus on energy transition and clean fuels. He will be responsible for the full line products, sales and solutions related to LNG and Hydrogen

“Stefan’s industry and market experience will be of great benefit to the Group, as we work to develop the opportunities in this region” according to Ole Jensen, Vice President, Nikkiso Clean Energy & Industrial Gases Europe.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages TG Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – TGTX

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TG Therapeutics, Inc. (NASDAQ: TGTX) between January 15, 2020 and May 31, 2022, both dates inclusive (the “Class Period”), of the important September 16, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TG Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TG Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=7662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab (an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (“CLL”), and relapsing forms of multiple sclerosis) and Umbralisib (or UKONIQ, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma); (2) accordingly, it was unlikely that TG Therapeutics would be able to obtain U.S. Food and Drug Administration (“FDA”) approval of the marginal zone lymphoma (“MZL”) and follicular lymphoma (“FL”) (the “Umbralisib MZL/FL NDA”), the rolling submission of a Biologics License Application (“BLA”) to the FDA for Ublituximab in combination with Umbralisib (together, “U2”), as a treatment for patients with CLL (the “U2 BLA”), the supplemental New Drug Application (“sNDA”) for Umbralisib to add an indication for CLL and small lymphocytic lymphoma (“SLL”) in combination with Ublituximab (the “U2 sNDA”), or the Ublituximab as a treatment for patients with relapsing forms of multiple sclerosis (“RMS”) (the “Ublituximab RMS BLA”) in their current forms; (3) as a result, TG Therapeutics had significantly overstated Ublituximab and Umbralisib’s clinical and/or commercial prospects; and (4) therefore, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TG Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=7662 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages MINISO Group Holding Limited Investors to Inquire About Securities Class Action Investigation – MNSO

NEW YORK, Aug. 08, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of MINISO Group Holding Limited (NYSE: MNSO) resulting from allegations that MINISO may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased MINISO securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=7814 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On July 26, 2022, during trading hours, market analyst Blue Orca Capital published a report regarding MINISO Group Holding Limited which alleges several issues with the Company including that “MINISO Lies about its Core Business Model” because “MINISO claims that 99% of its stores in China, its key market, are operated by franchisees independent from the Company. … Through our investigation, … we found over 620 supposedly independent franchises, which, according to Chinese corporate records, are registered under the names of MINISO executives or individuals closely connected to the Company’s chairman[,]” and “MINISO Admitted in Chinese Media that 40% of Stores Directly Owned.” The report further alleges that “IPO Proceeds Siphoned by Chairman through Crooked Headquarters Deal.” Finally, the report alleges that MINISO is a “Retailer In Decline: Shrinking Revenues, Falling Franchise Fees and Store Closures[,]” due in part to “Franchise Fees Dropped by 63%, Indicating Lagging Interest.”

On this news, MINISO American Depositary Share (ADS) price fell $1.08 per ADS, or 14%, to close at $6.13 per ADS on July 26, 2021, on unusually heavy trading volume. On July 27, 2022, MINISO’s ADSs closed at $5.66 per ADS, representing more than a 70% decline from the $20.00 IPO price.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results

DREAM enrollment complete, 12-month clinical data expected in fall of 2023

Mont-Saint-Guibert, Belgium – August 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022.

Second Quarter 2022 Financial and Operating Highlights

  • Completed enrollment in DREAM U.S. pivotal trial; expect 12-month clinical data in the fall of 2023 and regulatory approval in the first half of 2024
  • Generated revenue of €935,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents growth of more than five times the amount achieved in the second quarter of 2021
  • Activated 11 new implanting sites in Germany during the second quarter, bringing the total to 26 as of June 30, 2022; expecting to have at least 35 active implanting sites by the end of 2022
  • Received FDA approval of IDE submission to commence the ACCCESS study to treat complete concentric collapse (CCC) patients in the U.S., with first patient implant expected in the fourth quarter of 2022
  • Received FDA approval of the next generation Genio® 2.1 system for use in the DREAM study and CE mark for use in commercial patients in Europe; this improves patient comfort and compliance with a new smartphone application and upgraded external activation chip, which leverages Nyxoah’s scalable platform to continuously enhance patient comfort and therapy efficacy without requiring a new implant
  • Partnered with Acurable to distribute the AcuPebble SA100 wearable home sleep test to OSA patients in Germany; launch is expected in the fourth quarter of 2022
  • Included in the newly formed Euronext Tech Leaders Index, which is composed of 100+ innovative and high-growth technology companies with greater than €1 trillion in aggregate market capitalization

“We made significant progress on all of our key strategic priorities this quarter, including activating 11 new commercial sites in Germany, completing enrollment in our DREAM trial, and receiving approval for our ACCCESS IDE,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “From a commercial standpoint, our second quarter performance showing 42% quarter-over-quarter growth strengthens our confidence that we will achieve market leadership status in Germany by the end of 2022.”

“As the only commercially available hypoglossal nerve stimulation (HGNS) therapy approved for the treatment of CCC patients, we are encouraged by the first strong results from patients who are six months post-implantation. These results, combined with no longer having to perform a drug-induced sleep endoscopy (DISE) procedure prior to implant, are driving physicians to recommend Genio for their CCC and non-CCC patients,” continued Mr. Taelman.

Mr. Taelman concluded, “In the meantime, we have already begun investing in our U.S. market access organization. As for our ACCCESS study, we expect to implant the first patients before year end.”

Second Quarter and First Half 2022 Results

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2022 (in thousands)

 

For the three months ended June 30 For the six months ended June 30
2022 2021 2022 2021
Revenue € 935 € 170 € 1 595 € 355
Cost of goods sold (€ 334) (€ 63) (€ 623) (€ 115)
Gross profit € 601  € 107    € 972  € 240 
Research and Development Expense (€ 3 470) (€ 2 398) (€ 7 065) (€ 5 492)
Selling, General and Administrative Expense (€ 4 536) (€ 3 913) (€ 8 729) (€ 6 279)
Other income/(expense) € 14 (€ 101) € 150 (€ 97)
Operating loss for the period (€ 7 391) (€ 6 305) (€ 14 672) (€ 11 628)
Financial income € 4 670 € 39 € 6 246 € 43
Financial expense (€ 2 162) (€ 574) (€ 2 950) (€ 899)
Loss for the period before taxes (€ 4 883) (€ 6 840) (€ 11 376) (€ 12 484)
Income taxes (€ 107) (€ 99) (€ 315) (€ 124)
Loss for the period (€ 4 990) (€ 6 939) (€ 11 691) (€ 12 608)
         
Loss attributable to equity holders (€ 4 990) (€ 6 939) (€ 11 691) (€ 12 608)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences (€ 12) € 262 (€ 114) € 192
Total comprehensive loss for the year, net of tax (€ 5 002) (€ 6 677) (€ 11 805) (€ 12 416)
Loss attributable to equity holders (€ 5 002) (€ 6 677) (€ 11 805) (€ 12 416)
Basic Loss Per Share (in EUR) (€ 0,193) (€ 0,314) (€ 0,453) (€ 0,570)
Diluted Loss Per Share (in EUR) (€ 0,193) (€ 0,314) (€ 0,453) (€ 0,570)

 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT JUNE 30, 2022 (in thousands)

      As at
June 30
 2022
  December 31 2021
ASSETS
Non-current assets      
Property, plant and equipment € 2 111 € 2 020
Intangible assets 32 570   25 322
Right of use assets 3 410 3 218
Deferred tax asset     1 429   46
Other long-term receivables 180 164
    € 39 700   € 30 770
Current assets      
Inventory     506   346
Trade receivables 957 226
Other receivables     1 548   2 286
Other current assets 852 1 693
Financial assets 47 717
Cash and cash equivalents 75 602 135 509
  € 127 182 € 140 060
Total assets € 166 882 € 170 830
   
EQUITY AND LIABILITIES
Capital and reserves    
Capital 4 438 4 427
Share premium 228 158   228 033
Share based payment reserve   4 411 3 127
Other comprehensive income 88   202
Retained loss   (98 850) (87 167)
Total equity attributable to shareholders € 138 245 € 148 622
     
LIABILITIES
Non-current liabilities    
Financial debt 8 089   7 802
Lease liability   2 859 2 737
Pension liability 80   80
Provisions   44 12
Deferred tax liability   5
€ 11 072 € 10 636
Current liabilities    
Financial debt 661   554
Lease liability   672 582
Trade payables 4 301   3 995
Current tax liability 4 391   2 808
Other payables 7 540   3 633
  € 17 565 € 11 572
Total liabilities € 28 637 € 22 208
Total equity and liabilities € 166 882 € 170 830

 UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION – INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS AS AT JUNE 30, 2022 (in thousands)

      For the six months ended June 30
2022   2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year     € (11 376)   € (12 484)
Adjustments for
Finance income (6 246) (43)
Finance expenses 2 950 899
Depreciation and impairment of property, plant and equipment and right-of-use assets 536 377
Amortization of intangible assets 402 428
Share-based payment transaction expense 1 292
Increase/(Decrease) in provisions 32
Other non-cash items 37 11
Cash generated before changes in working capital € (12 373) € (10 812)
Changes in working capital
Decrease/(Increase) in inventory (160) (27)
(Increase)/Decrease in trade and other receivables 1 011 (3 463)
Increase/(Decrease) in trade and other payables 2 053 6 061
Cash generated from changes in operations € (9 469) € (8 241)
Income tax paid ( 254) ( 111)
Net cash used in operating activities € (9 723) € (8 352)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment (302) (795)
Capitalization of intangible assets (7 650) (3 726)
(Increase)/Decrease in financial assets – current (44 032)
Net cash used in investing activities € (51 984) € (4 521)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities (317) (236)
Repayment of other loan (42) (42)
Interests paid (134) (258)
Repayment of recoverable cash advance (105)
Proceeds from issuance of shares, net of transaction costs 136 362
Other financial costs (8) (10)
Net cash generated from financing activities € (365) € (289)
Movement in cash and cash equivalents € (62 072) € (13 162)
Effect of exchange rates on cash and cash equivalents 2 165 33
Cash and cash equivalents at January 1 € 135 509 € 92 300
Cash and cash equivalents at June 30 € 75 602 € 79 171

Revenue

Revenue was €935,000 for the second quarter ending June 30, 2022, compared to €170,000 for the second quarter ending June 30, 2021. Revenue for the first half of 2022 was €1.6 million, compared to €355,000 for the first half of 2021. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €334,000 for the three months ending June 30, 2022, representing a gross profit of €601,000, or gross margin of 64.3%. This compares to total cost of goods sold of €63,000 in the second quarter of 2021, for a gross profit of €107,000, or gross margin of 62.9%.

For the six months ending June 30, 2022, total cost of goods sold was €623,000, representing a gross profit of €972,000, or gross margin of 60.9%. This compares to total cost of goods sold of €115,000 in the first half of 2021, for a gross profit of €240,000, or gross margin of 67.6%.

Research and Development Expenses

Research and Development expenses were €3.5 million for the three months ending June 30, 2022, versus €2.4 million for the prior year period, reflecting the Company’s investments in the development of next generation versions of the Genio® system as well as ongoing clinical studies, most notably DREAM in the U.S.

For the six months ending June 30, 2022, Research and Development expenses were €7.1 million, versus €5.5 million for the first half of 2021.

Selling, General and Administrative Expenses

Selling, General and Administrative expenses rose to €4.5 million for the second quarter of 2022, up from €3.9 million in the second quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of the U.S. commercial launch.

For the six months ending June 30, 2022, Selling, General and Administrative expenses were €8.7 million, up from €6.3 million in the first half of 2021 due to increased commercial efforts in Germany and investments in Nyxoah’s corporate infrastructure.

Operating Loss

Total operating loss for the second quarter and first half of 2022 was €7.4 million and €14.7 million, respectively, versus €6.3 million and €11.6 million in the second quarter and first half of 2021, respectively. This was driven by the acceleration in the Company’s R&D spending, as well as ongoing commercial and clinical activities. Nyxoah realized a net loss of €5.0 million and €11.8 million for the second quarter and first half of 2022, respectively, compared to a net loss of €6.7 million and €12.4 million for the second quarter and first half of 2021, respectively.

Cash Position

As of June 30, 2022, cash and financial assets totaled €123.3 million, compared to €135.5 million on December 31, 2021.  Total cash burn was approximately €2.0 million per month during the first half of 2022. Nyxoah expects monthly cash burn to increase in the second half of 2022 to account for the commencement of the ACCCESS IDE trial in the U.S., and the current cash position provides ample liquidity to get to U.S. commercialization in 2024.

First Half 2022 Report

Nyxoah’s financial report for the first half of 2022, including details of the audited consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation 
Nyxoah will conduct a conference call open to the public today at 10:30 p.m. CET / 4:30 p.m. ET, which will also be webcast. To participate in the conference call, please access the following link to register for a dial-in number: https://register.vevent.com/register/BIfc3a52c9352e4e42958e9d816245b3b9

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com

+1 917 749 14

Attachment

Internet Society Foundation announces second round of innovation grants to address connectivity gap

US$200,000 grants available to advance Internet access and connectivity globally

RESTON, Va., Aug. 9, 2022 /PRNewswire/ — The Internet Society Foundation has launched a second round of grants to advance Internet access and connectivity around the world. Now in its second year, the The Building Opportunities/Leveraging Technologies (BOLT) grant program supports teams of creatives, technologists, and researchers to develop solutions to Internet connectivity, particularly among communities where current technologies are unavailable or inaccessible. US$200,000 grants will be awarded to organizations for projects lasting up to 12 months.

Internet Society Foundation

“The Internet Society Foundation is committed to using our funding to address the challenges that prevent people from accessing the Internet, in line with our vision that the Internet is for everyone. With almost half of the world population still offline, these grants aim to bolster the development of imaginative and sustainable solutions that will promote greater Internet access and connectivity for communities around the world”, noted Sarah Armstrong, Executive Director of the Internet Society Foundation.

The BOLT program builds on the Internet Society Foundation’s commitment to support innovative solutions to Internet connectivity. Organizations currently implementing projects around the world through the program include: Digital Empowerment Foundation, Digital Harbor Foundation Inc., Fundación Sole Colombia and the Research and Education Network for Uganda (RENU).

BOLT is open for applications between 8 August and 2 September and the grantees will be announced in October. Applying teams must ensure that their lead organization is a legally registered 501(c)(3) or equivalent.

See grant details and application process.

About The Internet Society Foundation:

The Internet Society Foundation was established in 2019 to support the positive difference the Internet can make to people everywhere. Guided by our vision of an Internet for Everyone, the Foundation champions ideas and enables communities to unlock the Internet’s potential to tackle the world’s evolving challenges. Focusing in five program areas, the Foundation awards grants to Internet Society Chapters as well as non-profit organizations and individuals dedicated to providing meaningful access to an open, globally connected, secure and trustworthy Internet for everyone.

Logo – https://mma.prnewswire.com/media/1866485/Internet_Society_Foundation_Logo.jpg